CeriBell's (NASDAQ:CBLL) Quiet Period To End on November 20th

CeriBell's (NASDAQ:CBLL - Get Free Report) quiet period will end on Wednesday, November 20th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CBLL shares. William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an "outperform" rating on the stock. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price target on the stock. Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a "buy" rating and a $30.00 price target on the stock. Bank of America began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a "buy" rating and a $32.00 price target on the stock. Finally, TD Cowen began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a "buy" rating and a $31.00 price target on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $31.20.

CeriBell Stock Down 3.4 %

NASDAQ CBLL traded down $0.97 on Wednesday, hitting $27.88. 204,238 shares of the stock were exchanged, compared to its average volume of 236,871. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.